Does crysvita have a biosimilar?

Does CrysVita (burosumab) have a biosimilar?

No. As of the information available here, CrysVita (burosumab) does not have an approved biosimilar. CrysVita is a biologic (a monoclonal antibody), and no biosimilar entry for burosumab is indicated in the provided materials.

When would a burosumab biosimilar be expected to appear?

A burosumab biosimilar typically could be expected only after key regulatory and market exclusivity periods end for CrysVita, and once a biosimilar manufacturer submits and receives approval for the necessary evidence of similarity and quality. Specific dates are not provided in the available information here.

Are there alternatives to CrysVita if biosimilars aren’t available?

If you’re asking because of access or cost, the main alternatives would depend on the exact condition being treated (for example, tumor-induced osteomalacia vs. X-linked hypophosphatemia). The available information here doesn’t list specific substitute drugs or therapies.

What to check to confirm biosimilar availability in your country

Biosimilar availability is country-specific and can change quickly. To confirm current status, check:
- Your national regulator’s biologics/biosimilars search tool (e.g., FDA’s biologics listings in the US, EMA’s medicines listings in the EU).
- The product listing for “burosumab” or for the brand “CrysVita” to see whether any follow-on biologic/biosimilar is listed.

Sources:
None provided in the prompt.